- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07839013
Brain Function and Cognitive Control Training in Children With Obsessive-Compulsive Symptoms (AKILI - OCS)
The goal of this clinical trial is to learn about brain function and cognition in children ages 8-12 who have subclinical obsessive-compulsive symptoms (OCS), such as unwanted thoughts or repetitive behaviors. The study will also examine whether patterns of brain activity are related to how children respond to cognitive training.
The main questions this study aims to answer are:
- Are there different patterns of brain activity related to cognitive control among children with OCS?
- Are these patterns related to differences in OCS or cognition?
- Can brain activity before training help predict changes in cognitive control or OCS severity after cognitive training?
Participants will:
- Complete clinical interviews, questionnaires, and tests of cognition.
- Have a magnetic resonance imaging scan while completing a cognitive control task.
- Complete video-game-based cognitive training on an iPad for about 25 minutes a day, 5 days a week, for 4 weeks.
- Complete another set of clinical interviews and questionnaires after the training.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Dana Diaz
- Phone Number: (646) 774-5128
- Email: ChildBrainTrain@nyspi.columbia.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Irving Medical Center
-
Contact:
- Dana Diaz
- Phone Number: (646) 774-5128
- Email: ChildBrainTrain@nyspi.columbia.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 8 to 12 years at the time of consent (i.e., 8.00 - 12.99 years).
- Will have definite obsession(s) and/or compulsion(s)
- NO current or lifetime history of meeting DSM-5 criterion B for OCD.
- Not on psychotropic medication (either treatment-naïve or free of psychotropic medication for at least one month) or on stable medication regime for ADHD (e.g., stimulants).
- Capacity to provide written informed assent by the participants and permission by the parent/guardian.
Exclusion Criteria:
- DSM-5 current major depressive disorder.
- DSM-5 current or lifetime diagnosis of OCD, PTSD, substance/alcohol abuse, psychotic disorder, bipolar disorder, eating disorder, pervasive developmental disorder.
- Current or lifetime history of a major medical or neurological problem (e.g., unstable hypertension, seizure disorder, major head trauma).
- Active suicidal ideation with some intent to act.
- Presence of metallic device (ferromagnetic implants or dental braces).
- Females who are pregnant or nursing.
- Wechsler Abbreviated Scale of Intelligence II Full-scale IQ <80.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cognitive Training for Subclinical Obsessive-Compulsive Symptoms
This is an open-label, one-arm study. Children who have subclinical obsessive-compulsive symptoms (CY-BOCS score 1-12) will complete 4-weeks of at-home cognitive training. |
Digital, at-home cognitive training program (AKL-T01) delivered on iPad (25 minutes/day, 5 days/week) for 4 weeks. Styled as a child-friendly video game, AKL-T01 cognitive training taps skills like focused attention, response inhibition, and working memory using a series of games with individually titrated difficulty to engage cognitive control processes.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
NIH Toolbox Cognition Battery
Time Frame: Baseline, post-cognitive training (4 weeks)
|
Standardized Fluid Cognition Composite Score derived from the NIH Toolbox Cognition Battery. Scores are norm-referenced with a mean of 100 and standard deviation of 15; higher scores indicate better cognitive functioning. |
Baseline, post-cognitive training (4 weeks)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dana Diaz, PhD, Columbia University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- ACYY1655
- 1K01MH141273-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.